story of the week
Genomic Differences Between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer and Neoadjuvant Chemotherapy Outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Genomic Differences Between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy
Eur Urol 2018 Oct 02;[EPub Ahead of Print], EJ Pietzak, EC Zabor, A Bagrodia, J Armenia, W Hu, A Zehir, S Funt, F Audenet, D Barron, N Maamouri, Q Li, MY Teo, ME Arcila, MF Berger, N Schultz, G Dalbagni, HW Herr, DF Bajorin, JE Rosenberg, H Al-Ahmadie, BH Bochner, DB Solit, G IyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.